Olmutinib

CHEMBL3786343 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
486.6 g/mol
LogP
4.7
Phase
4

A third-generation EGFR inhibitor that targets the T790M resistance mutation in non-small cell lung cancer, developed to treat patients who have progressed on earlier EGFR inhibitors. It selectively blocks mutant EGFR signaling while sparing the normal form of the receptor.

น้ำหนักโมเลกุล

486.6000 g/mol

LogP

4.70

TPSA

111.00 Ų

Lipinski RO5

ผ่าน

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1

InChI

InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

Molecular Formula

C26H26N6O2S

HBD / HBA

2 / 8

พันธะที่หมุนได้

7

อะตอมหนัก

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A third-generation EGFR inhibitor that targets the T790M resistance mutation in non-small cell lung cancer, developed to treat patients who have progressed on earlier EGFR inhibitors. It selectively blocks mutant EGFR signaling while sparing the normal form of the receptor.

Yes, Olmutinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3786343. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54758501. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.